Evidence map›Paper›PMID 31301110›Full record

ArticleCancer medicine2019

Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI.

Katrina M Ingley, Sally M Burtenshaw, Nicole C Theobalds, Lawrence M White, Martin E Blackstein, Rebecca A Gladdy, Seng Thipphavong, Abha A Gupta

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Katrina M IngleyDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON.ORCID https://orcid.org/0000-0002-1806-2686
Sally M BurtenshawDivision of General Surgery, Sinai Health System, Department of Surgery, University of Toronto, Toronto, ON.
Nicole C TheobaldsDivision of Medical Oncology and Hematology, Sinai Health System, Toronto, ON.
Lawrence M WhiteDepartment of Medical Imaging, University of Toronto, Toronto, ON.
Martin E BlacksteinDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON.
Rebecca A GladdyDivision of General Surgery, Sinai Health System, Department of Surgery, University of Toronto, Toronto, ON.
Seng ThipphavongToronto Joint Department of Medical Imaging, University Health Network, Sinai Health System and Women's College Hospital, Toronto, ON.
Abha A GuptaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON.
Princess Margaret Cancer Centre · CAUniversity of Toronto · CASinai Health System · CAUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDesmoid fibromatosis (DF) is a rare fibroblastic proliferation that was historically treated with surgery. We report (a) outcomes using low-dose chemotherapy, methotrexate (MTX), and vinorelbine (VNL) for patients with progressing disease (PD) and (b) whether tumor volume (V

methodsPatients with biopsy-proven DF, treated with MTX/VNL from 1997 to 2015 were reviewed. MRI for a subset of patients was independently re-evaluated for response by RECIST, V

resultsAmong 48 patients treated for a median 19 months MTX/VNL, only nine (19%) had previous surgery. RECIST-based overall response rate was complete response (CR) 20 (42%) + partial response (PR) 19 (39%), stable disease (SD) 8 (17%), for a clinical benefit rate of 98%. The median progression-free survival (PFS) was 120 months, (95%CI 84-155 months). Thirty-six (75%) patients had not progressed at a median 38 months from treatment completion. Most common grade 1/2 toxicities included nausea (n = 12, 25%) and fatigue (n = 9,19%) with no grade 3/4 toxicities. In 22 patients with serial MRIs, there was a decrease in D

conclusionLow-dose MTX/VNL for a defined duration has high efficacy with sustained benefit and minimal toxicity for treating DF. V

Indexed as

Magnetic Resonance ImagingAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDesmoid TumorsFemaleHumansKaplan-Meier EstimateMaleMethotrexateMiddle AgedNeoplasm StagingRemission InductionResponse Evaluation Criteria in Solid TumorsTreatment OutcomeMethotrexateVinorelbineaggressive fibromatosisdesmoid fibromatosismethotrexate/vinorelbine chemotherapyMR imagingT2 signaltumor volume

Identifiers

PMID31301110
PMCPMC6718598
OpenAlexW2956720022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.